What is Medable?
Headquartered in Palo Alto, California, Medable operates as a critical technology bridge in the life sciences industry. By providing a comprehensive platform for clinical trial execution, the company enables pharmaceutical and biotech organizations to transition toward decentralized and hybrid research models. This shift is essential for modernizing clinical research, as it facilitates the seamless collection of patient-generated data, thereby enhancing the precision and predictive capabilities of medical studies. Medable's market position is defined by its commitment to reducing the friction inherent in traditional trial processes, ultimately accelerating the delivery of life-saving therapies to patients worldwide.
How much funding has Medable raised?
Medable has raised a total of $518.8M across 6 funding rounds:
Series A
$3.6M
Series B
$16.2M
Debt
$1M
Other Financing Round
$25M
Series C
$169M
Series D
$304M
Series A (2015): $3.6M, investors not publicly disclosed
Series B (2018): $16.2M, investors not publicly disclosed
Debt (2020): $1M supported by PPP
Other Financing Round (2020): $25M featuring PPD, Inc and GSR Ventures
Series C (2021): $169M backed by Sapphire Ventures LLC, The Obvious, Streamline Ventures, GSR Ventures, and PPD Group Inc
Series D (2021): $304M with participation from Blackstone Accelerates Growth, Tiger Global Management, WTI - Western Telematic, Sapphire Ventures, and GSR Ventures
Key Investors in Medable
Tiger Global Management
Tiger Global Management is a prominent investment firm that deploys capital across both public and private markets, focusing on high-growth technology and internet companies.
Blackstone Accelerates Growth
Blackstone Accelerates Growth (BxG) is an initiative focused on fostering entrepreneurship and economic development by supporting innovative programs that drive job creation and company scaling.
Sapphire Ventures
Sapphire Ventures is a venture capital firm based in Palo Alto, specializing in providing growth capital and strategic services to technology companies looking to scale their operations.
What's next for Medable?
Following this major strategic investment, Medable is well-positioned to scale its operational footprint and deepen its technological moat. The company is expected to prioritize the expansion of its decentralized clinical trial (DCT) capabilities, focusing on interoperability and data security to meet the rigorous demands of enterprise-level pharmaceutical partners. As the industry continues to embrace digital transformation, Medable's focus on predictive medicine and patient-centric research will likely serve as a primary growth engine. Future initiatives will likely involve enhancing the platform's analytical depth and expanding its reach into emerging markets, ensuring that the company remains at the forefront of the clinical research innovation cycle.
See full Medable company page
